Discovery of TERN-501, a Selective THR-Agonist for the Treatment of Non- Alcoholic Steatohepatitis

Time: 11:00 am
day: Day 1 Stream 1 AM

Details:

• Learning about TERN-501: A liver-distributed, highly selective agonist of thyroid hormone receptor beta (THR-b)
• Discovering how TERN-501 has been designed to be metabolically stable to reduce pharmacokinetic variability, allowing for a low clinical dose and potential use in a fixeddose combination
• Hearing how TERN-501 significantly improves lipid parameters and reduces steatosis in preclinical models of hypercholesteremia and NASH

Speakers: